TY - JOUR
T1 - Hepatitis C elimination among people who inject drugs
T2 - Challenges and recommendations for action within a health systems framework
AU - the International Network on Hepatitis in Substance Users (INHSU)
AU - Day, Emma
AU - Hellard, Margaret
AU - Treloar, Carla
AU - Bruneau, Julie
AU - Martin, Natasha K.
AU - Øvrehus, Anne
AU - Dalgard, Olav
AU - Lloyd, Andrew
AU - Dillon, John
AU - Hickman, Matt
AU - Byrne, Jude
AU - Litwin, Alain
AU - Maticic, Mojca
AU - Bruggmann, Philip
AU - Midgard, Havard
AU - Norton, Brianna
AU - Trooskin, Stacey
AU - Lazarus, Jeffrey V.
AU - Grebely, Jason
N1 - Funding Information:
Gilead Sciences and Merck/MSD outside of this work. CT has nothing to declare. NM has received unrestricted research grants and honoraria from Gilead Sciences and Merck outside of this work. OD has received research funding from Abbvie Gilead Sciences and MSD and is on advisory boards for Abbvie and MSD outside of this work. JD has received grant/research support from AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Roche, Genedrive and speaker honoraria from AbbVie, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Roche outside of this work. JB has nothing to declare. AL is a consultant/advisor and has received research grants from Gilead Sciences and Merck/MSD outside of this work. MM has nothing to declare. PB is a consultant/advisor and has received research/travel grants from AbbVie, Gilead Sciences and Merck/MSD outside of this work. BN has nothing to declare. ST has received grant support from Gilead Sciences outside of this work.
Funding Information:
The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. NM is supported by the National Institute for Drug Abuse [grant number R01 DA037773] and the University of California San Diego Center for AIDS Research (CFAR), a National Institute of Health (NIH)-funded programme [grant number P30 AI036214]. The authors wish to thank Tim France for preparing the original figure Ref. which has been adapted for Figure.
Funding Information:
The authors received no funding from any pharmaceutical company in relation to this work. ED has nothing to declare. JG is a consultant/advisor and has received research grants from AbbVie, Cepheid, Gilead Sciences and Merck/MSD outside of this work. JVL is a consultant/advisor or has received research grants from AbbVie, Cepheid,
Funding Information:
TheKirbyInstituteisfundedbytheAustralianGovernmentDepartment of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. JG is supported by a National Health and Medical Research Council Career Development Fellowship. NM is supported by the National Institute for Drug Abuse [grant number R01 DA037773] and the University of California San Diego Center for AIDS Research (CFAR), a National Institute of Health (NIH)-funded programme [grant number P30 AI036214]. The authors wish to thank Tim France for preparing the original figure Ref. 134 which has been adapted for Figure 2.
Publisher Copyright:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2019/1
Y1 - 2019/1
N2 - The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an estimated prevalence of 39%, representing an estimated 6.1 million people who have recently injected drugs living with hepatitis C infection. As such, PWID are a priority population for enhancing prevention, testing, linkage to care, treatment and follow-up care in order to meet World Health Organization (WHO) hepatitis C elimination goals by 2030. There are many barriers to enhancing hepatitis C prevention and care among PWID including poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. On 5 September 2017, the International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of international experts to discuss remaining challenges and future priorities for action from a health systems perspective. The WHO health systems framework comprises six core components: service delivery, health workforce, health information systems, medical procurement, health systems financing, and leadership and governance. Communication has been proposed as a seventh key element which promotes the central role of affected community engagement. This review paper presents recommended strategies for eliminating hepatitis C as a major public health threat among PWID and outlines future priorities for action within a health systems framework.
AB - The burden of hepatitis C infection is considerable among people who inject drugs (PWID), with an estimated prevalence of 39%, representing an estimated 6.1 million people who have recently injected drugs living with hepatitis C infection. As such, PWID are a priority population for enhancing prevention, testing, linkage to care, treatment and follow-up care in order to meet World Health Organization (WHO) hepatitis C elimination goals by 2030. There are many barriers to enhancing hepatitis C prevention and care among PWID including poor global coverage of harm reduction services, restrictive drug policies and criminalization of drug use, poor access to health services, low hepatitis C testing, linkage to care and treatment, restrictions for accessing DAA therapy, and the lack of national strategies and government investment to support WHO elimination goals. On 5 September 2017, the International Network of Hepatitis in Substance Users (INHSU) held a roundtable panel of international experts to discuss remaining challenges and future priorities for action from a health systems perspective. The WHO health systems framework comprises six core components: service delivery, health workforce, health information systems, medical procurement, health systems financing, and leadership and governance. Communication has been proposed as a seventh key element which promotes the central role of affected community engagement. This review paper presents recommended strategies for eliminating hepatitis C as a major public health threat among PWID and outlines future priorities for action within a health systems framework.
KW - elimination
KW - health systems
KW - people who inject drugs
KW - viral hepatitis C
UR - http://www.scopus.com/inward/record.url?scp=85053681021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053681021&partnerID=8YFLogxK
U2 - 10.1111/liv.13949
DO - 10.1111/liv.13949
M3 - Review article
C2 - 30157316
AN - SCOPUS:85053681021
SN - 1478-3223
VL - 39
SP - 20
EP - 30
JO - Liver International
JF - Liver International
IS - 1
ER -
